Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Brian Moore who wrote (15383)	2/19/1998 6:11:00 PM
From: Henry Niman	Respond to of 32384

KS stand for Kaposi Sacoma. It is fairly common among men with AIDS. There are 20-25,000 cases in the US and an equal number in Europe. LGND is filing for approval in both markets (this quarter for the US and shortly thereafter for Europe - one of the Phase III trials was done in Europe, Canada, US, and Australia). CTCL is Cutaneous T-Cell Lymphoma. It's market is somewhat smaller than KS, but current treatments are very expensive $25,000-$40,000. LGND expects each market to be in the $50 million range. Analysts have projected sales to hit about $500 million if some of the larger cancer markets demonstrate efficacy (which we should know shortly).

To: Brian Moore who wrote (15383)	2/19/1998 6:16:00 PM
From: tonyt	Respond to of 32384

Here's some current news: SAN DIEGO, Feb. 19 /PRNewswire/ -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced the election, by the Board of Directors, of James R. Mirto, Vice President Marketing and Business Development, to officer of the corporation. "Jim's extensive experience in pharmaceuticals sales and marketing, particularly in the field of oncology spanning more than 20 years, has enabled him to establish a solid foundation for Ligand's commercial program for 1998 and 1999. In recognition of Jim's contributions to Ligand's commercial development over the past four years, the Board of Directors of Ligand has elected Jim an officer of the company," said David E. Robinson, Chairman, President and Chief Executive Officer. Mr. Mirto joined Ligand in August 1993 as Vice President, New Product Development and Licensing and became Vice President, Marketing and Business Development in October 1996. Prior to joining Ligand, he served as Vice President of New Product Planning and Development at Immunex Corporation from November 1992 to August 1993 where he oversaw tactical and strategic planning, collaborative arrangements and world-wide licensing activities. From 1987 to 1992, he worked for Adria Laboratories, a division of Erbamont, where he last served as Vice President of Sales and Marketing from April 1990 to November 1992 and was responsible for the company's oncology and general pharmaceuticals. From 1977 to 1987, Mr. Mirto held a number of managerial positions at the United States Pharmaceutical and Nutritional Group, a division of Bristol-Myers. As eastern regional manager for Bristol-Myers' Oncology Division in Philadelphia from 1985 to 1987, he was directly involved in several oncology product launches. Mr. Mirto received a bachelor of science degree in Health and Physical Education from Slippery Rock State College in Pennsylvania, and earned a master of education degree at the University of Pittsburgh. Since 1989, Ligand Pharmaceuticals Incorporated has established a leadership position in gene transcription technology, particularly intracellular receptor (IR) technology and Signal Transducers and Activators of Transcription (STATs). Ligand has applied IR and STATs technology to the discovery and development of small molecule drugs to enhance therapeutic and safety profiles and to address unmet patient needs in cancer, women's and men's health and skin diseases, as well as osteoporosis, metabolic, cardiovascular and inflammatory disease. This press release may contain certain forward looking statements by Ligand and actual results could differ materially from those described as a result of factors, including, but not limited to, the following. There can be no assurance that any product will be successfully developed, that regulatory approvals will be granted, that patient and physician acceptance of these products will be achieved or that final results of human clinical trials will be consistent with any interim results, or that results will be supportive of regulatory approvals required to market products. Ligand undertakes no obligation to update the statements contained in this press release after the date hereof. SOURCE Ligand Pharmaceuticals Inc. -0- 02/19/98 /NOTE TO EDITORS: If you would prefer to receive Ligand's press releases via e-mail please inform us at investors@ligand.com and request to be placed on our priority e-mail list./ /CONTACT: Susan E. Atkins, Vice President, Corporate Communications & Investor Relations of Ligand Pharmaceuticals, 619-550-7687/ /Company News On-Call: prnewswire.com or fax, 800-758-5804, ext. 509313/

To: Brian Moore who wrote (15383)	2/19/1998 6:27:00 PM
From: Henry Niman	Read Replies (2) \| Respond to of 32384

Promotion of the director of marketing and sales is a good sign that Ligand expects him to be VERY busy in the upcoming months.

To: Brian Moore who wrote (15383)	2/19/1998 6:30:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

Here's more news. Looks like LGND is getting ready to make and sell PRODUCTS! Philip A. Duffy Named Vice President, Technical Operations at Ligand Pharmaceuticals Inc. Thursday, February 19, 1998 05:56 PM > SAN DIEGO, Feb. 19 /PRNewswire/ -- Ligand Pharmaceuticals Inc. (Nasdaq: LGND) has announced the appointment of Philip A. Duffy to the newly created position of Vice President, Technical Operations. Mr. Duffy will oversee Ligand's chemical, formulations and analytical development activities for commercial products, as well as manufacturing, purchasing, and materials management functions. Prior to joining Ligand, Mr. Duffy served as Vice President, Product Supply for Schein Bayer Pharmaceutical Services, Inc., a position he held since 1994. From 1993 to 1994, he was the principal of Philip A. Duffy & Associates, a New Jersey-based pharmaceutical consulting practice. From 1992 to 1993, he was Corporate Vice President, Materials Management at ICN Pharmaceuticals Inc. Mr. Duffy has held management positions with a number of pharmaceutical companies during the past 20 years, including careers with Schering-Plough Inc., G.D. Searle & Co., and Baxter International. Mr. Duffy earned a bachelor of arts degree in Economics from Marquette University and an MBA in Management and Organization Behavior at George Williams College. He served in the U.S. Army from 1966 until 1969, and completed Officer Candidate School for the U.S. Army Transportation Corps in 1967. In recognition of his service, Mr. Duffy was awarded the Bronze Star with Oak Leaf Cluster, the Army Commendation Medal with "Valor" and Vietnam Service Ribbons. Ligand Pharmaceuticals Incorporated, founded in 1987, is a leader in gene transcription technology, particularly intracellular receptors (IR) technology and Signal Transducers and Activators of Transcription (STATs). Ligand has applied IR and STATs technology to the discovery and development of small molecule drugs to enhance therapeutic and safety profiles and to address major unmet patient needs in cancer, women's and men's health and skin diseases, as well as osteoporosis, metabolic, cardiovascular and inflammatory disease. This press release may contain certain forward looking statements by Ligand and actual results could differ materially from those described as a result of factors, including, but not limited to, the following. There can be no assurance that any product will be successfully developed, that regulatory approvals will be granted, that patient and physician acceptance of these products will be achieved or that final results of human clinical trials will be consistent with any interim results, or that results will be supportive of regulatory approvals required to market products. Ligand undertakes no obligation to update the statements contained in this press release after the date hereof. SOURCE Ligand Pharmaceuticals Inc. CONTACT: Susan E. Atkins, Vice President, Corporate Communications & Investor Relations of Ligand Pharmaceuticals, 619-550-7687